A highly anticipated test of an experimental Ebola vaccine will begin this week at the National Institutes of Health, amid mounting anxiety about the spread of the deadly virus in West Africa
The experimental vaccine, developed by the pharmaceutical company GlaxoSmithKline and the NIAID, will first be given to three healthy human volunteers to see if they suffer any adverse effects. If deemed safe, it will then be given to another small group of volunteers, aged 18 to 50, to see if it produces a strong immune response to the virus. All will be monitored closely for side effects.
click here!
This comment has been removed by the author.
ReplyDeleteI think they should speed up the process. Maybe try it on the actual patients effected by the outbreak. I know it's not proven to work yet but when you have something like this, it's either they're cured or they die. In my opinion, testing the vaccine on healthy subjects may just be a waste of time. Of course, no one should be forced to have it tested one them. They should offer it to any volunteers just like they would have to do for cancer research or anything of the like.
ReplyDelete